French fintech Worldline cuts guidance
By Mauro Orru
Worldline slashed its forecasts for the year due to volatile spending across Europe.
The French fintech company (FR:WLN) said it now expects organic revenue growth of about 2% to 3% this year, compared with a previous forecast of at least 3%. Adjusted earnings before interest, taxes, depreciation and amortization-Worldline's preferred measure of profitability-should come in between roughly 1.13 billion euros and 1.17 billion euros ($1.22 billion-$1.27 billion), compared with a previous forecast of at least EUR1.17 billion.
Free cash flow should amount to about EUR230 million, compared with previous guidance of at least EUR230 million.
"As witnessed by many companies in consumer-driven industries, the European domestic consumption trends have slowed down during the second quarter and the speed of a potential recovery remains uncertain at this stage," said Chief Executive Gilles Grapinet.
In the second quarter, Worldline reported EUR1.19 billion in revenue, up 1.7% from a year earlier on an organic basis. Analysts had forecast EUR1.19 billion, according to consensus estimates compiled by Visible Alpha.
For the first six months, Worldline reported a net loss of EUR29 million, compared with profit of EUR81 million a year earlier. Adjusted Ebitda slipped to EUR514 million from EUR518 million.
Write to Mauro Orru at mauro.orru@wsj.com
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-01-24 0345ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks